NRG1 and neoplasm: Given clinical data implicating NRG1 upregulation in poor outcomes on ADT, it is tempting to speculate that patients may benefit from pre-therapy selection by NRG1 immunohistochemistry on tumor specimens or by sNRG1 detection in the blood.